Kevzara is intended to treat patients with moderate to severe rheumatoid arthritis who do not respond to other treatments. The drug is administered via a subcutaneous injection once every two weeks.
Kevzara will cost $39,000 annually for the 150 milligram and 200 milligram doses. Sanofi and Regneron said this figure marks a 30 percent decrease from the cost of two the rival drugs on the market.
More articles on supply chain:
McKesson 2017 revenue up 4%: 5 things to know
What Trump’s budget proposal means for FDA funding
Baking soda shortage forces hospitals to postpone surgeries, treatments
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
